e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
AtlasClear Holdings, Inc. Common Stock
SiNtx Technologies, Inc. - Common Stock
Edit Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Iambic Therapeutics, Inc. - Common Stock
(NQ:
IAM
)
14.94
+0.72 (+5.06%)
Delayed Quote
Updated: 2:21 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Iambic Therapeutics, Inc. - Common Stock
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Today 8:00 EST
From
Iambic Therapeutics Inc
Via
GlobeNewswire
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
November 16, 2026
From
Iambic Therapeutics Inc
Via
GlobeNewswire
Iambic to participate in Jefferies Global Healthcare Conference
November 09, 2026
Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026
From
Iambic Therapeutics Inc
Via
GlobeNewswire
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
October 26, 2026
From
Iambic Therapeutics, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.